Researchers at McGill University in Montreal, Canada conducted an open-label intervention pilot study to analyze the effect of the cannabinoids THC, CBD with THC, and CBD without THC.
Over a 12-week period, the researchers took ten people living with HIV and randomly gave them some of the dosages to corroborate the therapeutic safety of the extracts.
Each individual had their maximum and minimum dose adjusted. The first was 15 mg THC/15 MG CBD and a maximum of 800 mg CBD.
The primary outcome was the percentage of participants without significant toxicity according to levels reported by the World Health Organization (WHO). Cannabinoids did not alter hematological/biochemical profiles.
“With anti-inflammatory properties, cannabinoids may be a potential strategy to reduce immune activation in people living with HIV (PLWHA), but more information is needed on their safety and tolerability,” the research says.
The researchers concluded that HIV patients tolerate varied cannabinoid use quite well.
“In PLWHA, cannabinoids appear generally safe and well tolerated, although larger studies are needed. Screening for occult liver pathology should be performed and liver enzymes monitored, especially with high doses of CBD.”
Full article: https://pubmed.ncbi.nlm.nih.gov/36551926/
in Costa Rica. 
